Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded
British Journal of Dermatology · 17.07.2026 · 195 (2) · 200-201
DOI: 10.1093/bjd/ljag166 ↗Kurz gefasst
Kommentar in der Zeitschrift British Journal of Dermatology, online erschienen am 05.05.2026. Verfasst von David Saceda-Corralo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, University Hospital Ramón y Cajal, Madrid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
David Saceda-Corralo, Sergio Vañó-Galván; TYK2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded, British Journal of Dermato
Autor:innen und Institutionen
- Dermatology Department, University Hospital Ramón y Cajal, Madrid, Spain.
- Hair Disorders Unit, Grupo Pedro Jaén, Madrid, Spain.
ORCID-Profile: David Saceda-Corralo, Sergio Vañó-Galván
Zitieren
APA
Saceda-Corralo, D., & Vañó-Galván, S. (2026). Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded. British Journal of Dermatology, 195(2), 200-201. https://doi.org/10.1093/bjd/ljag166
Vancouver
Saceda-Corralo D, Vañó-Galván S. Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded. British Journal of Dermatology. 2026;195(2):200-201. doi:10.1093/bjd/ljag166
BibTeX
@article{SacedaCorralo2026,
author = {Saceda-Corralo, David and Vañó-Galván, Sergio},
title = {Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded},
journal = {British Journal of Dermatology},
year = {2026},
volume = {195},
number = {2},
pages = {200--201},
doi = {10.1093/bjd/ljag166}
}
EUVIMED